Search results for "Socio-culturale"

showing 10 items of 201 documents

Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study

2016

Background: Atrial fibrillation (AF) is associated with a substantial risk of thromboembolism and mortality, significantly reduced by oral anticoagulation. Adherence to guidelines may lower the risks for both all cause and cardiovascular (CV) deaths. Methods: Our objective was to evaluate if antithrombotic prophylaxis according to the 2012 European Society of Cardiology (ESC) guidelines is associated to a lower rate of adverse outcomes. Data were obtained from REPOSI; a prospective observational study enrolling inpatients aged ≥65 years. Patients enrolled in 2012 and 2014 discharged with an AF diagnosis were analysed. Results: Among 2535 patients, 558 (22.0 %) were discharged with a diagnos…

Antithrombotic therapy; Atrial fibrillation; Elderly; Guidelines; Outcomes; Cardiology and Cardiovascular MedicineMaleRegistrieTime Factorsantithrombotic therapy; atrial fibrillation; elderly; guidelines; outcomesAtrial fibrillation (AF)Practice PatternsKaplan-Meier Estimate030204 cardiovascular system & hematologyGuidelineoutcomesCoronary artery disease0302 clinical medicineElderlyRisk FactorsAtrial FibrillationAntithrombotic80 and overAge Factor030212 general & internal medicineRegistriesguidelinesAntithrombotic therapy Atrial fibrillation Elderly Guidelines OutcomesPractice Patterns Physicians'OutcomeAged 80 and overFibrinolytic AgentAge FactorsAtrial fibrillationGeneral MedicineTreatment OutcomeItalyAtrial fibrillation (AF) thromboembolism antithrombotic prophylaxisPractice Guidelines as TopicCardiologyFemaleGuideline AdherenceCardiology and Cardiovascular MedicineHumanAntithrombotic therapy; Atrial fibrillation; Elderly; Guidelines; Outcomes; Age Factors; Aged; Aged 80 and over; Atrial Fibrillation; Chi-Square Distribution; Female; Fibrinolytic Agents; Guideline Adherence; Humans; Italy; Kaplan-Meier Estimate; Logistic Models; Male; Practice Patterns Physicians'; Proportional Hazards Models; Registries; Risk Assessment; Risk Factors; Thromboembolism; Time Factors; Treatment Outcome; Practice Guidelines as Topic; Cardiology and Cardiovascular Medicinemedicine.medical_specialtyLogistic ModelTime FactorSocio-culturaleLower riskRisk Assessment03 medical and health sciencesFibrinolytic AgentsInternal medicineThromboembolismmedicineHumansProportional Hazards ModelsAgedAntithrombotic therapyPhysicians'Chi-Square Distributionbusiness.industryProportional hazards modelRisk FactorSettore MED/09 - MEDICINA INTERNAGuidelinethromboembolismmedicine.diseaseAtrial fibrillationLogistic ModelsProportional Hazards Modelantithrombotic prophylaxisbusinessChi-squared distributionFibrinolytic agent
researchProduct

Minimal clinically important difference for asthma endpoints: an expert consensus report

2020

Minimal clinically important difference (MCID) can be defined as the smallest change or difference in an outcome measure that is perceived as beneficial and would lead to a change in the patient's medical management.The aim of the current expert consensus report is to provide a “state-of-the-art” review of the currently available literature evidence about MCID for end-points to monitor asthma control, in order to facilitate optimal disease management and identify unmet needs in the field to guide future research.A series of MCID cut-offs are currently available in literature and validated among populations of asthmatic patients, with most of the evidence focusing on outcomes as patient repo…

Asthma asthma management minimal clinically important difference end-pointsPulmonary and Respiratory Medicinemedicine.medical_specialtyConsensusDelphi TechniqueEndpoint DeterminationBronchoconstrictionMEDLINEDelphi methodSocio-culturaleSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOminimal clinically important difference; asthma; lung function; biomarkersMCID03 medical and health sciences0302 clinical medicinePredictive Value of TestsmedicineHumansAnti-Asthmatic Agents030212 general & internal medicineDisease management (health)Intensive care medicineLungAsthmalcsh:RC705-779business.industryMinimal clinically important differenceminimal clinically important differenceExpert consensusend-pointslcsh:Diseases of the respiratory systemmedicine.diseaseMCID asthmaAsthmaTreatment Outcome030228 respiratory systemPredictive value of testsEndpoint DeterminationInflammation MediatorsSymptom AssessmentbusinessBiomarkersasthma managementEuropean Respiratory Review
researchProduct

Search for heavy neutral lepton production in K+ decays to positrons

2020

A search for heavy neutral lepton ($N$) production in $K^+\to e^+N$ decays using the data sample collected by the NA62 experiment at CERN in 2017--2018 is reported. Upper limits of the extended neutrino mixing matrix element $|U_{e4}|^2$ are established at the level of $10^{-9}$ over most of the accessible heavy neutral lepton mass range 144--462 MeV/$c^2$, with the assumption that the lifetime exceeds 50 ns. These limits improve significantly upon those of previous production and decay searches. The $|U_{e4}|^2$ range favoured by Big Bang Nucleosynthesis is excluded up to a mass of about 340 MeV/$c^2$.

AstrofísicaNuclear and High Energy PhysicsHeavy neutral lepton kaon meson kaon decay positronPontecorvo–Maki–Nakagawa–Sakata matrixSocio-culturaleFOS: Physical sciencesNA62 experiment7. Clean energy01 natural sciencesNA62High Energy Physics - ExperimentNuclear physicsHigh Energy Physics - Experiment (hep-ex)Positronkaon decays heavy neutral lepton SM extensionsPE2_2Big Bang nucleosynthesisSM extensionskaon physics0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]010306 general physicsComputingMilieux_MISCELLANEOUSPhysicsRange (particle radiation)Large Hadron Colliderkaon decays010308 nuclear & particles physicshep-exSettore FIS/04Heavy neutral leptonlepton flavour violationFísicalcsh:QC1-999kaon mesonkaon decaykaon physics; lepton flavour violation; NA62positronProduction (computer science)High Energy Physics::Experimentkaonlcsh:PhysicsParticle Physics - ExperimentLepton
researchProduct

Carotid plaque detection improves the predictve value of CHA2DS2-VASc score in patients with non-valvular atrial fibrilation: The ARAPACIS Study

2017

Abstract Background and aims Vascular disease (VD), as assessed by history of myocardial infarction or peripheral artery disease or aortic plaque, increases stroke risk in atrial fibrillation (AF), and is a component of risk assessment using the CHA 2 DS 2 -VASc score. We investigated if systemic atherosclerosis as detected by ultrasound carotid plaque (CP) could improve the predictive value of the CHA 2 DS 2 -VASc score. Methods We analysed data from the ARAPACIS study, an observational study including 2027 Italian patients with non-valvular AF, in whom CP was detected using Doppler Ultrasonography. Results VD was reported in 351 (17.3%) patients while CP was detected in 16.6% patients. Ad…

Atherosclerosis Atrial fibrillation Carotid plaque CHA2DS2-VASc score Stroke Vascular diseaseCarotid Artery DiseasesMaleAtherosclerosis; Atrial fibrillation; Carotid plaque; CHA2DS2-VASc score; Stroke; Vascular disease; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Carotid Artery Diseases; Female; Humans; Incidence; Italy; Male; Plaque Atherosclerotic; Retrospective Studies; Risk Factors; Survival Rate; Ultrasonography Doppler; Risk Assessment; Cardiology and Cardiovascular Medicine030204 cardiovascular system & hematologyatrialf fibrillation0302 clinical medicineRetrospective StudieRisk FactorsCarotid artery diseaseAtherosclerosis; Atrial fibrillation; Carotid plaque; CHA; 2; DS; 2; -VASc score; Stroke; Vascular disease; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Carotid Artery Diseases; Female; Humans; Incidence; Italy; Male; Plaque Atherosclerotic; Retrospective Studies; Risk Factors; Survival Rate; Ultrasonography Doppler; Risk AssessmentAtrial Fibrillation80 and over030212 general & internal medicineMyocardial infarctionStrokeDSAtherosclerosis; Atrial fibrillation; CHA(2)DS(2)-VASc score; Carotid plaque; Stroke; Vascular disease; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Carotid Artery Diseases; Female; Humans; Incidence; Italy; Male; Plaque Atherosclerotic; Retrospective Studies; Risk Factors; Survival Rate; Ultrasonography Doppler; Risk AssessmentCHA 2 DS 2 -VASc scorePlaqueAtheroscleroticUltrasonographyAged 80 and overIncidenceDopplerAtrial fibrillationCarotid plaquePlaque AtheroscleroticStrokeSurvival RateItalyAtherosclerosiCHA(2)DS(2)-VASc scoreCardiologyartherosclerosis; atrial fibrillation; carotid plaque; CHA2DS2-VASc score; stroke; vascular disease; aged; aged 80 and over; ankle brachial index; atrialf fibrillation; carotid artery diseases; female; humans; incidence; italy; male; plaque atherosclerotic; retrospective studies; risk factors; survival rate; ultrasonography doppler; risk assessment; cardiology and cardiovascular medicineFemaleSettore SECS-S/01 - StatisticaCardiology and Cardiovascular MedicineHumanmedicine.medical_specialtyCHA2DS2-VASc score2Atherosclerosis; Atrial fibrillation; Carotid plaque; CHA 2 DS 2 -VASc score ; Stroke; Vascular disease; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Carotid Artery Diseases; Female; Humans; Incidence; Italy; Male; Plaque Atherosclerotic; Retrospective Studies; Risk Factors; Survival Rate; Ultrasonography Doppler; Risk Assessment; Cardiology and Cardiovascular MedicineSocio-culturaleVascular diseaseRisk Assessment-VASc score03 medical and health sciencesInternal medicinemedicineHumansAnkle Brachial Indexcardiovascular diseasesRisk factorSurvival rateAgedRetrospective StudiesCarotid Artery DiseaseVascular diseasebusiness.industryRisk FactorUltrasonography Dopplermedicine.diseaseAtherosclerosisartherosclerosisCHA2DS2–VASc scoreCHAAtherosclerosis; Atrial fibrillation; Carotid plaque; CHA; 2; DS; 2; -VASc score; Stroke; Vascular diseasebusiness
researchProduct

Coverage, efficacy or dosing interval: which factor predominantly influences the impact of routine childhood vaccination for the prevention of varice…

2016

Background Varicella is a highly infectious disease with a significant public health and economic burden, which can be prevented with childhood routine varicella vaccination. Vaccination strategies differ by country. Some factors are known to play an important role (number of doses, coverage, dosing interval, efficacy and catch-up programmes), however, their relative impact on the reduction of varicella in the population remains unclear. This paper aims to help policy makers prioritise the critical factors to achieve the most successful vaccination programme with the available budget. Methods Scenarios assessed the impact of different vaccination strategies on reduction of varicella disease…

Budgets0301 basic medicineMalePediatricsNational Health ProgramsNational Health ProgramDiseaseVaricella0302 clinical medicineChickenpoxEpidemiology030212 general & internal medicineChildChickenpox Vaccineeducation.field_of_studyChickenpoxlcsh:Public aspects of medicineImmunization ProgramVaccinationvirus diseasesCoverage; Dosing interval; Efficacy; Routine varicella vaccination impact; VaricellaVaccinationItalyBudgetDosing intervalFemalePublic HealthResearch ArticleHumanmedicine.medical_specialtyCoverageAdolescentEfficacy030106 microbiologyPopulationSocio-culturaleVaccines AttenuatedMass VaccinationRoutine varicella vaccination impactChickenpox Vaccine03 medical and health sciencesCoverage; Dosing interval; Efficacy; Routine varicella vaccination impact; Varicella; Public Health Environmental and Occupational HealthmedicineHumansDosingeducationImmunization Programsbusiness.industryEnvironmental and Occupational HealthPublic Health Environmental and Occupational Healthlcsh:RA1-1270Models Theoreticalmedicine.diseaseVaccine efficacybusinessBMC Public Health
researchProduct

Is vaginal fractional CO2 laser treatment effective in improving overactive bladder symptoms in post-menopausal patients? Preliminary results

2016

To evaluate the role of vaginal fractional CO2 laser treatment in the relief of Overactive Bladder (OAB) symptoms in post-menopausal women.Post-menopausal women who complained of one or more symptoms related to vulvo-vaginal atrophy (VVA), who experienced symptoms of OAB and who underwent vaginal treatment with fractional CO2 laser were enrolled in the study. At baseline (T0) and 30 days post-treatment T1), vaginal status (using Vaginal Health Index - VHI), subjective intensity of VVA symptoms (using a visual analog scale - VAS) and micturition diary were evaluated. OAB symptoms were also assessed using a validated questionnaire.Thirty patients were enrolled. A statistically significant imp…

CO2 laserUrinary Bladder OveractiveOveractive bladderSocio-culturalePostmenopauseAdministration IntravaginalTreatment OutcomeLasers GasQuality of LifeCO2 laser Overactive bladder Menopause Vulvo-vaginal atrophy.HumansFemaleMenopauseVulvo-vaginal atrophyCO2 laser Overactive bladder Menopause Vulvo-vaginal atrophy
researchProduct

Risk factors associated with adverse fetal outcomes in pregnancies affected by Coronavirus disease 2019 (COVID-19): a secondary analysis of the WAPM …

2020

Abstract Objectives To evaluate the strength of association between maternal and pregnancy characteristics and the risk of adverse perinatal outcomes in pregnancies with laboratory confirmed COVID-19. Methods Secondary analysis of a multinational, cohort study on all consecutive pregnant women with laboratory-confirmed COVID-19 from February 1, 2020 to April 30, 2020 from 73 centers from 22 different countries. A confirmed case of COVID-19 was defined as a positive result on real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of nasal and pharyngeal swab specimens. The primary outcome was a composite adverse fetal outcome, defined as the presence of either abortion (pre…

COVID-19 VaccineInfectious Disease TransmissionPerinatal DeathAbortionClinical Laboratory TechniqueMiscarriageCohort Studies0302 clinical medicineCOVID-19 TestingPregnancyRisk Factors3123 Gynaecology and paediatricsSecondary analysisPerinatal medicineAbortion SpontaneouMedicineVertical030212 general & internal medicineViralPregnancy Complications Infectiouscoronavirus; perinatal morbidity; perinatal mortality; covid-19Coronavirus; perinatal morbidity; perinatal mortality; Abortion Spontaneous; COVID-19; COVID-19 Testing; COVID-19 Vaccines; Clinical Laboratory Techniques; Cohort Studies; Coronavirus Infections; Female; Gestational Age; Humans; Infant Newborn; Infant Premature; Infectious Disease Transmission Vertical; Pandemics; Pneumonia Viral; Pregnancy; Pregnancy Complications Infectious; Pregnancy Outcome; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; SARS-CoV-2; Betacoronavirus; Fetal Death; Perinatal Deathperinatal morbidity030219 obstetrics & reproductive medicineObstetricsReverse Transcriptase Polymerase Chain ReactionInfectiousPregnancy OutcomeGestational ageObstetrics and Gynecology3. Good healthSettore MED/40perinatal mortalityGestationFemaleCoronavirus InfectionsInfant PrematureHumanmedicine.medical_specialtyCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)CoronaviruPneumonia ViralSocio-culturaleGestational AgeIntrauterine deviceCoronavirus; perinatal morbidity; perinatal mortality03 medical and health sciencesBetacoronavirusPARVOVIRUS B19 INFECTIONCoronavirus perinatal morbidity perinatal mortalityHumansAdverse effectPrematurePandemicsFetal DeathPregnancyFetusBetacoronaviruPandemicCoronavirus Infectionbusiness.industryClinical Laboratory TechniquesSARS-CoV-2Risk FactorSpontaneousMORTALITYInfant NewbornAbortionCOVID-19InfantOdds ratioPneumoniamedicine.diseaseNewbornInfectious Disease Transmission VerticalAbortion SpontaneousPregnancy ComplicationsCoronavirusPediatrics Perinatology and Child HealthPregnancy Complications InfectiouCohort StudiebusinessCoronavirus; perinatal mortality; perinatal morbidityJournal of perinatal medicine
researchProduct

The EUROCARE-5 study on cancer survival in Europe 1999-2007: Database, quality checks and statistical analysis methods

2015

Abstract Background Since 25 years the EUROCARE study monitors the survival of cancer patients in Europe through centralised collection, quality check and statistical analysis of population-based cancer registries (CRs) data. The European population covered by the study increased remarkably in the latest round. The study design and statistical methods were also changed to improve timeliness and comparability of survival estimates. To interpret the EUROCARE-5 results on adult cancer patients better here we assess the impact of these changes on data quality and on survival comparisons. Methods In EUROCARE-5 the survival differences by area were studied applying the complete cohort approach to…

Cancer ResearchSurvivalPopulationSocio-culturalePopulation-based registriesPopulation-based registrieQuality checksCancer; EUROCARE; Europe; Population-based registries; Quality checks; Survival; Oncology; Cancer ResearchMedicineeducationCancereducation.field_of_studyRelative survivalbusiness.industryPopulation sizeComparabilityCancerPercentage pointmedicine.diseaseQuality checkEuropeOncologyData qualityCohortbusinessEUROCARECancer ; EUROCARE ; Europe ; Population-based registries ; Quality checks ; SurvivalDemography
researchProduct

Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999- 2007: Results…

2015

Abstract Background The EUROCARE study collects and analyses survival data from population-based cancer registries (CRs) in Europe in order to provide data on between-country differences in survival and time trends in survival. Methods This study analyses data on liver cancer, gallbladder and extrahepatic biliary tract cancers (“biliary tract cancers”), and pancreatic cancer diagnosed in 2000–2007 from 88 CRs in 29 countries. Relative survival (RS) was estimated overall, by region, sex, age and period of diagnosis using the complete approach. Time trends in 5-year RS over 1999–2007 were also analysed using the period approach. Results The prognosis of the studied cancers was poor. Age-stand…

Cancer Researchmedicine.medical_specialtySurvivalBiliary tract cancer; Cancer registry; Europe; Pancreatic cancer; Primary liver cancer; Survival; Time trends in survival; Oncology; Cancer ResearchPopulationSocio-culturaleTime trends in survivalGastroenterologyInternal medicinePancreatic cancermedicineeducationSurvival analysiseducation.field_of_studyRelative survivalbusiness.industryGallbladderPrimary liver cancerCancerPancreatic cancerCancer registrymedicine.diseaseCancer registryEuropeBiliary tract cancer ; Cancer registry ; Europe ; Pancreatic cancer ; Primary liver cancer ; Survival ; Time trends in survivalmedicine.anatomical_structureOncologyBiliary tract cancerLiver cancerbusiness
researchProduct

Incidence trends of colorectal cancer in the early 2000s in Italy. Figures from the IMPATTO study on colorectal cancer screening

2015

We utilised the IMPATTO study's archives to describe the 2000-2008 colorectal cancer (CRC) incidence rate trends in Italy, once screening programmes based on the faecal immunochemical test were implemented in different areas. Data on CRCs diagnosed in Italy from 2000 to 2008 in subjects aged 40-79 years were collected by 23 cancer registries. Incidence rate trends were evaluated as a whole and by macro-area (North-Centre and South-Islands), presence of a screening programme, sex, ten-year age class, anatomic site, stage at diagnosis, and pattern of diagnosis (screen-detected, non-screen-detected). The annual percent change (APC) of incidence rate trends, with 95% confidence intervals (95%CI…

Colorectal cancer; Fecal immunochemical test; Incidence rates; Italy; Screening; Epidemiology; Public Health Environmental and Occupational HealthItalyFecal immunochemical testEpidemiologyEnvironmental and Occupational HealthScreeningPublic Health Environmental and Occupational HealthSocio-culturaleIncidence ratesPublic HealthIncidence rateSettore MED/42 - Igiene Generale E ApplicataColorectal cancer
researchProduct